BR112015008285B1 - Processo para preparar uma formulação farmacêutica particulada - Google Patents
Processo para preparar uma formulação farmacêutica particulada Download PDFInfo
- Publication number
- BR112015008285B1 BR112015008285B1 BR112015008285-8A BR112015008285A BR112015008285B1 BR 112015008285 B1 BR112015008285 B1 BR 112015008285B1 BR 112015008285 A BR112015008285 A BR 112015008285A BR 112015008285 B1 BR112015008285 B1 BR 112015008285B1
- Authority
- BR
- Brazil
- Prior art keywords
- particles
- water
- coating
- process according
- core particles
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 8
- 239000002245 particle Substances 0.000 claims abstract description 329
- 238000000576 coating method Methods 0.000 claims abstract description 204
- 239000011248 coating agent Substances 0.000 claims abstract description 177
- 238000000034 method Methods 0.000 claims abstract description 93
- 229920000642 polymer Polymers 0.000 claims abstract description 93
- 230000008569 process Effects 0.000 claims abstract description 63
- 239000000463 material Substances 0.000 claims abstract description 60
- 238000002156 mixing Methods 0.000 claims abstract description 54
- 235000019640 taste Nutrition 0.000 claims abstract description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 239000008186 active pharmaceutical agent Substances 0.000 claims abstract description 7
- 239000004698 Polyethylene Substances 0.000 claims description 118
- 229920000573 polyethylene Polymers 0.000 claims description 118
- 239000001993 wax Substances 0.000 claims description 110
- 239000007771 core particle Substances 0.000 claims description 109
- 238000004090 dissolution Methods 0.000 claims description 93
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 72
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 34
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 34
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 34
- 239000000377 silicon dioxide Substances 0.000 claims description 30
- 229920003176 water-insoluble polymer Polymers 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 29
- 238000007922 dissolution test Methods 0.000 claims description 20
- -1 polyethylene Polymers 0.000 claims description 20
- 230000002209 hydrophobic effect Effects 0.000 claims description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 9
- 239000000796 flavoring agent Substances 0.000 claims description 9
- 235000019634 flavors Nutrition 0.000 claims description 9
- 229920001477 hydrophilic polymer Polymers 0.000 claims description 9
- 239000008101 lactose Substances 0.000 claims description 9
- 239000004203 carnauba wax Substances 0.000 claims description 7
- 235000013869 carnauba wax Nutrition 0.000 claims description 7
- 238000007873 sieving Methods 0.000 claims description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 5
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 4
- 239000004810 polytetrafluoroethylene Substances 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 239000008055 phosphate buffer solution Substances 0.000 claims description 3
- WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 claims description 2
- 239000004952 Polyamide Substances 0.000 claims description 2
- 239000004743 Polypropylene Substances 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- 229920000193 polymethacrylate Polymers 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims 1
- 239000005977 Ethylene Substances 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 abstract description 28
- 239000003814 drug Substances 0.000 abstract description 19
- 229940079593 drug Drugs 0.000 abstract description 18
- 239000002904 solvent Substances 0.000 abstract description 7
- 238000001035 drying Methods 0.000 abstract description 3
- 229920001600 hydrophobic polymer Polymers 0.000 abstract 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 226
- 239000011668 ascorbic acid Substances 0.000 description 113
- 235000010323 ascorbic acid Nutrition 0.000 description 113
- 229960005070 ascorbic acid Drugs 0.000 description 113
- 239000010410 layer Substances 0.000 description 40
- 238000012545 processing Methods 0.000 description 38
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 34
- 229960001680 ibuprofen Drugs 0.000 description 34
- 238000001878 scanning electron micrograph Methods 0.000 description 25
- 238000009472 formulation Methods 0.000 description 18
- 230000000873 masking effect Effects 0.000 description 18
- 238000009826 distribution Methods 0.000 description 15
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 14
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 10
- 229930006000 Sucrose Natural products 0.000 description 10
- 239000010419 fine particle Substances 0.000 description 10
- 239000011521 glass Substances 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 238000005259 measurement Methods 0.000 description 10
- 230000009467 reduction Effects 0.000 description 10
- 239000005720 sucrose Substances 0.000 description 10
- 238000005054 agglomeration Methods 0.000 description 9
- 230000002776 aggregation Effects 0.000 description 9
- 239000008199 coating composition Substances 0.000 description 9
- 239000011362 coarse particle Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000011324 bead Substances 0.000 description 7
- 239000011247 coating layer Substances 0.000 description 7
- 238000013270 controlled release Methods 0.000 description 7
- 239000004014 plasticizer Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 229910002012 Aerosil® Inorganic materials 0.000 description 6
- 239000000654 additive Substances 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 238000000227 grinding Methods 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- 238000003801 milling Methods 0.000 description 6
- 239000002195 soluble material Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 239000001856 Ethyl cellulose Substances 0.000 description 4
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 229920001249 ethyl cellulose Polymers 0.000 description 4
- 235000019325 ethyl cellulose Nutrition 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000007909 solid dosage form Substances 0.000 description 4
- 235000019658 bitter taste Nutrition 0.000 description 3
- 238000005253 cladding Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000003116 impacting effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 230000009967 tasteless effect Effects 0.000 description 3
- 238000009736 wetting Methods 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- MCMNRKCIXSYSNV-UHFFFAOYSA-N Zirconium dioxide Chemical compound O=[Zr]=O MCMNRKCIXSYSNV-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000000498 ball milling Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 230000009477 glass transition Effects 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- MADRVGBADLFHMO-UHFFFAOYSA-N Indeloxazine Chemical compound C=1C=CC=2C=CCC=2C=1OCC1CNCCO1 MADRVGBADLFHMO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229960000981 artemether Drugs 0.000 description 1
- 125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960001803 cetirizine Drugs 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229920001688 coating polymer Polymers 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- SXYIRMFQILZOAM-HVNFFKDJSA-N dihydroartemisinin methyl ether Chemical compound C1C[C@H]2[C@H](C)CC[C@H]3[C@@H](C)[C@@H](OC)O[C@H]4[C@]32OO[C@@]1(C)O4 SXYIRMFQILZOAM-HVNFFKDJSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009506 drug dissolution testing Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 229960004333 indeloxazine Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000010954 inorganic particle Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000003990 inverse gas chromatography Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960000916 niflumic acid Drugs 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000006069 physical mixture Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000011164 primary particle Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000003566 sealing material Substances 0.000 description 1
- 238000005549 size reduction Methods 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000004441 surface measurement Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/651,977 US9107851B2 (en) | 2012-10-15 | 2012-10-15 | Solventless mixing process for coating pharmaceutical ingredients |
| US13/651,977 | 2012-10-15 | ||
| PCT/US2013/064058 WO2014062444A1 (en) | 2012-10-15 | 2013-10-09 | Solventless mixing process for coating pharmaceutical ingredients |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015008285A2 BR112015008285A2 (pt) | 2017-07-04 |
| BR112015008285B1 true BR112015008285B1 (pt) | 2022-11-16 |
Family
ID=49474713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015008285-8A BR112015008285B1 (pt) | 2012-10-15 | 2013-10-09 | Processo para preparar uma formulação farmacêutica particulada |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US9107851B2 (enExample) |
| EP (1) | EP2906205B1 (enExample) |
| JP (1) | JP6159504B2 (enExample) |
| CN (1) | CN104853751B (enExample) |
| AR (1) | AR093013A1 (enExample) |
| BR (1) | BR112015008285B1 (enExample) |
| CY (1) | CY1121241T1 (enExample) |
| DK (1) | DK2906205T3 (enExample) |
| ES (1) | ES2688889T3 (enExample) |
| HR (1) | HRP20181463T1 (enExample) |
| HU (1) | HUE039772T2 (enExample) |
| PL (1) | PL2906205T3 (enExample) |
| PT (1) | PT2906205T (enExample) |
| RS (1) | RS57918B1 (enExample) |
| SI (1) | SI2906205T1 (enExample) |
| WO (1) | WO2014062444A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016011412A1 (en) | 2014-07-17 | 2016-01-21 | Ada Technologies, Inc. | Extreme long life, high energy density batteries and method of making and using the same |
| CN104587472B (zh) * | 2014-12-31 | 2017-12-15 | 广东国方医药科技有限公司 | 一种含纳米SiO2的包衣剂及其制备方法 |
| US10217571B2 (en) | 2015-05-21 | 2019-02-26 | Ada Technologies, Inc. | High energy density hybrid pseudocapacitors and method of making and using the same |
| US12401042B2 (en) | 2015-06-01 | 2025-08-26 | Forge Nano Inc. | Nano-engineered coatings for anode active materials, cathode active materials, and solid-state electrolytes and methods of making batteries containing nano-engineered coatings |
| US12027661B2 (en) | 2015-06-01 | 2024-07-02 | Forge Nano Inc. | Nano-engineered coatings for anode active materials, cathode active materials, and solid-state electrolytes and methods of making batteries containing nano-engineered coatings |
| US11996564B2 (en) | 2015-06-01 | 2024-05-28 | Forge Nano Inc. | Nano-engineered coatings for anode active materials, cathode active materials, and solid-state electrolytes and methods of making batteries containing nano-engineered coatings |
| US10692659B2 (en) | 2015-07-31 | 2020-06-23 | Ada Technologies, Inc. | High energy and power electrochemical device and method of making and using same |
| JP7069538B2 (ja) * | 2016-12-05 | 2022-05-18 | マルボシ酢株式会社 | 食酢含有飲料組成物 |
| US11024846B2 (en) | 2017-03-23 | 2021-06-01 | Ada Technologies, Inc. | High energy/power density, long cycle life, safe lithium-ion battery capable of long-term deep discharge/storage near zero volt and method of making and using the same |
| WO2019009335A1 (ja) * | 2017-07-04 | 2019-01-10 | 村上 正裕 | 微粒子の製造方法及び微粒子 |
| BR112021016485A2 (pt) * | 2019-02-22 | 2021-10-13 | Catalent U.K. Swindon Zydis Limited | Minimização de aglomeração de material de revestimento de partícula de fármaco durante armazenamento para estabilizar tempos de desintegração de produtos farmacêuticos |
| AR118418A1 (es) | 2019-02-22 | 2021-10-06 | Catalent Uk Swindon Zydis Ltd | Conservación de partículas ifa revestidas funcionalmente producidas mediante procesos de mezcla sin solvente en suspensión acuosa |
| CN113490486B (zh) | 2019-02-22 | 2025-10-17 | 康特伦英国斯温顿捷迪斯有限公司 | 最小化团聚、曝气和保持包含布洛芬的药物组合物的包衣 |
| CA3129383A1 (en) | 2019-02-22 | 2020-08-27 | Catalent U.K. Swindon Zydis Limited | Minimizing aeration of suspensions during in-line mixing |
| US20210009767A1 (en) * | 2019-07-11 | 2021-01-14 | International Flavors & Fragrances Inc. | Solventless particle coating via acoustic mixing |
| US12285731B2 (en) | 2019-09-12 | 2025-04-29 | United States Of America, As Represented By The Secretary Of The Army | Acoustic mixing system for creating propellant mixture |
| MX2023001004A (es) * | 2020-07-31 | 2023-03-01 | Catalent Uk Swindon Zydis Ltd | Composiciones farmaceuticas que comprenden un ingrediente farmaceutico activo (api) recubierto. |
| CN120053389A (zh) * | 2025-02-25 | 2025-05-30 | 江苏亚邦爱普森药业有限公司 | 一种含有替米沙坦药物的片剂及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5628945A (en) | 1992-08-03 | 1997-05-13 | Riman; Richard E. | Multicomponent powder mixing process and compositions produced thereby |
| WO1994015374A1 (fr) * | 1992-12-25 | 1994-07-07 | Tdk Corporation | Element secondaire au lithium |
| US5769917A (en) * | 1996-12-09 | 1998-06-23 | Belko; William C. | Process for producing low shrink ceramic bodies |
| US6740341B1 (en) | 1998-11-25 | 2004-05-25 | Cima Labs Inc. | Taste masking rapid release coating system |
| DE10062176A1 (de) * | 2000-12-14 | 2002-07-04 | Wacker Polymer Systems Gmbh | Polyvinylacetal-gepfropfte Polymerisate |
| US8163114B2 (en) | 2004-04-07 | 2012-04-24 | New Jersey Institute Of Technology | Netshape manufacturing processes and compositions |
| DE102004059792A1 (de) * | 2004-12-10 | 2006-06-14 | Röhm GmbH & Co. KG | Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Nukleinsäure-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform |
| US20060210694A1 (en) * | 2005-03-18 | 2006-09-21 | Chappell Rulon A | Anti-caking agents and methods |
| US7862848B2 (en) | 2005-08-03 | 2011-01-04 | The University Of Western Ontario | Direct coating solid dosage forms using powdered materials |
| WO2011155451A1 (ja) | 2010-06-08 | 2011-12-15 | 学校法人神戸学院 | コーティング粒子及びコーティング粒子の製造方法 |
| GB201205632D0 (en) | 2012-03-30 | 2012-05-16 | Vectura Ltd | Method and apparatus |
| US8993041B2 (en) * | 2012-10-15 | 2015-03-31 | New Jersey Institute Of Technology | Taste masked active pharmaceutical powder compositions and processes for making them |
-
2012
- 2012-10-15 US US13/651,977 patent/US9107851B2/en active Active
-
2013
- 2013-10-09 PL PL13780276T patent/PL2906205T3/pl unknown
- 2013-10-09 WO PCT/US2013/064058 patent/WO2014062444A1/en not_active Ceased
- 2013-10-09 DK DK13780276.5T patent/DK2906205T3/en active
- 2013-10-09 HR HRP20181463TT patent/HRP20181463T1/hr unknown
- 2013-10-09 CN CN201380053927.5A patent/CN104853751B/zh active Active
- 2013-10-09 ES ES13780276.5T patent/ES2688889T3/es active Active
- 2013-10-09 RS RS20181079A patent/RS57918B1/sr unknown
- 2013-10-09 SI SI201331167T patent/SI2906205T1/sl unknown
- 2013-10-09 EP EP13780276.5A patent/EP2906205B1/en active Active
- 2013-10-09 JP JP2015536852A patent/JP6159504B2/ja active Active
- 2013-10-09 HU HUE13780276A patent/HUE039772T2/hu unknown
- 2013-10-09 PT PT13780276T patent/PT2906205T/pt unknown
- 2013-10-09 BR BR112015008285-8A patent/BR112015008285B1/pt active IP Right Grant
- 2013-10-15 AR ARP130103731A patent/AR093013A1/es not_active Application Discontinuation
-
2018
- 2018-09-13 CY CY20181100951T patent/CY1121241T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2906205T3 (pl) | 2019-03-29 |
| CN104853751B (zh) | 2018-06-22 |
| CY1121241T1 (el) | 2020-05-29 |
| JP2015533162A (ja) | 2015-11-19 |
| EP2906205B1 (en) | 2018-06-13 |
| CN104853751A (zh) | 2015-08-19 |
| US20140106059A1 (en) | 2014-04-17 |
| HRP20181463T1 (hr) | 2018-12-14 |
| US9107851B2 (en) | 2015-08-18 |
| JP6159504B2 (ja) | 2017-07-05 |
| BR112015008285A2 (pt) | 2017-07-04 |
| DK2906205T3 (en) | 2018-09-24 |
| WO2014062444A1 (en) | 2014-04-24 |
| HUE039772T2 (hu) | 2019-02-28 |
| RS57918B1 (sr) | 2019-01-31 |
| AR093013A1 (es) | 2015-05-13 |
| EP2906205A1 (en) | 2015-08-19 |
| SI2906205T1 (sl) | 2018-12-31 |
| PT2906205T (pt) | 2018-11-07 |
| ES2688889T3 (es) | 2018-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9107851B2 (en) | Solventless mixing process for coating pharmaceutical ingredients | |
| TWI731321B (zh) | 醋酸阿比特龍配方 | |
| US20210038585A1 (en) | Niraparib formulations | |
| JP5357032B2 (ja) | 誤用抵抗性製剤 | |
| ES2745759T3 (es) | Polvo compuesto farmacéutico de núcleo y cubierta y procedimientos de fabricación del mismo | |
| US20210030735A1 (en) | Pediatric niraparib formulations and pediatric treatment methods | |
| JP6166859B2 (ja) | 味マスクされた活性医薬粉末組成物およびその製造方法 | |
| US11278496B2 (en) | Crystalline microspheres and the process of manufacturing the same | |
| Yadav et al. | Pharmaceutical pellets: a versatile carrier for oral controlled delivery of drugs | |
| MX2011001487A (es) | Uso de sucralosa como agente granulante. | |
| JP2012087073A (ja) | コーティング粒子の製造方法、及び該製造方法で製造されたコーティング粒子 | |
| JP4092587B2 (ja) | 二軸混練機を用いた乾式コーティング | |
| Hassan et al. | Taste masking of levofloxacin by microparticulate system using emulsion solvent evaporation technique | |
| CN102579398A (zh) | 一种具有掩盖药物不良口味作用的肠溶微囊及制备方法 | |
| JP2010200853A (ja) | コーティング粒子の製造方法 | |
| Lam | The making of liqui-pellet and liqui-tablet, the next generation oral dosage form | |
| Lam et al. | A novel application of an effervescent Agent in Naproxen Liqui-pellets for enhanced drug release | |
| Negi et al. | Overview on recent researches on floating microspheres | |
| MIN | A Study of Multiparticulate Drug Delivery Systems | |
| Elsergany | Particle Engineering for Multiparticulate Drug Delivery Systems | |
| JP2009520704A (ja) | 水溶性担体を持つコアを含むペレット | |
| Jaiswal Vicky et al. | FLOATING MICROSPHERE: AN APPROACH TO ORAL CONTROLLED DRUG DELIVERY VIA GASTRIC RETENTION. | |
| Pai et al. | Multiple Unit Particle System (MUPS): Novel technology for preparation of Extended Release (ER) tablets | |
| Di Pretoro | DEVELOPMENT OF AN ORAL MULTIPLE-UNIT DOSAGE FORM CONTAINING A HIGH LOAD OF 5-AMINOSALICYLIC ACID |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/10/2013, OBSERVADAS AS CONDICOES LEGAIS |